BNT162b2 mRNA Covid-19疫苗在青少年中的安全性和有效性
韩国对12年级学生自2021年7月19日起提供BNT162b2疫苗,10-11年级学生不符合条件。全国回顾性队列研究纳入444,313名首剂接种者,心肌炎和/或心包炎报告率首剂为每10万人1.8例(95%CI 0.8-3.5),第二剂为每10万人4.3例(95%CI 2.6-6.7);对有症状/无症状SARS-CoV-2感染的有效性首剂后14天为91.1%(95%CI 89.6-92.5),第二剂后14天为99.1%(95%CI 98.5-99.5)。
要点
- 首剂接种者心肌炎和/或心包炎报告率为每10万人1.8例(95%CI 0.8-3.5)。
- 第二剂接种者心肌炎和/或心包炎报告率为每10万人4.3例(95%CI 2.6-6.7)。
- 疫苗对SARS-CoV-2感染的有效性首剂后14天为91.1%,第二剂后14天为99.1%。
核心结论
- BNT162b2疫苗接种是安全的,并与SARS-CoV-2感染风险显著降低相关,提示青少年接种疫苗可能减轻Covid-19负担。
研究设计与样本
- 全国性回顾性队列研究,纳入444,313名接种首剂BNT162b2疫苗的青少年。
主要发现
- 首剂接种者心肌炎和/或心包炎报告率为每10万人1.8例(95%CI 0.8-3.5)。
- 第二剂接种者心肌炎和/或心包炎报告率为每10万人4.3例(95%CI 2.6-6.7)。
- 首剂接种后14天对有症状/无症状SARS-CoV-2感染的有效性为91.1%(95%CI 89.6-92.5)。
- 第二剂接种后14天对有症状/无症状SARS-CoV-2感染的有效性为99.1%(95%CI 98.5-99.5)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10th-11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8-3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6-6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6-92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5-99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV-2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19.
引用
- June Choe Y, Yi S, Hwang I, et al. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. Vaccine. 2021. PMID: 35012777. doi:10.1016/j.vaccine.2021.12.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。